Injectafer denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for injectafer are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Injectafer for Exceeding Quantity Limits

A quantity-limit denial means the amount of Injectafer (ferric carboxymaltose) requested — whether in total dose, number of infusion sessions, or frequency — exceeds what Humana's coverage policy permits within a defined period. Quantity limits for IV iron infusions are typically based on published dosing ranges in the FDA-approved prescribing label, but the plan's internal limit may be more restrictive than the label allows or may not account for the clinical complexity of individual patients.

This denial is appealable, especially when the prescriber can document clinical reasons why the standard quantity limit is insufficient for this patient's specific situation — such as ongoing blood loss, malabsorption, chronic disease requiring maintenance infusions, or an initial repletion need that exceeds the standard allotment.

## Federal Appeal Framework

ACA §2719 provides external review rights after internal appeal for non-grandfathered plans. ERISA §503 guarantees full-and-fair review for employer-sponsored plans. The external-review window is typically four months from denial. Expedited review is available if clinical urgency makes waiting for a standard timeline dangerous.

## Concrete Appeal Steps

1. Request Humana's written explanation of the specific quantity limit applied and the policy basis for it. 2. Compare the plan's limit to the dosing range in the current FDA-approved Injectafer prescribing label — if the plan limit is more restrictive than the label permits, note this explicitly in the appeal. 3. Have your prescriber document the clinical rationale for the requested quantity, including the patient's specific clinical factors that drive the need. 4. Submit the internal appeal within Humana's stated deadline. 5. If denied internally, file for external review within the four-month window.

## Documentation to Gather

• Diagnosis confirmation: Chart notes and labs establishing the underlying cause of iron deficiency and its severity.
• Ongoing loss or malabsorption documentation (if applicable): Evidence of a chronic condition causing continued iron depletion, explaining why a higher quantity is medically necessary.
• Prior-treatment response: Any prior infusion history, with dates and documented clinical response, demonstrating that the quantity limit was already met without achieving the therapeutic goal.
• Prescriber medical-necessity letter: Specifically addresses why the requested quantity is necessary beyond the standard limit, referencing the FDA-approved label's dosing guidance and the applicable clinical guideline organization.

## Criteria-Mapping Structure

Obtain the FDA-approved Injectafer prescribing label and Humana's published quantity-limit policy for IV iron replacement. Build a response table:

| Humana quantity-limit criterion | Supporting documentation | |---|---| | Diagnosis driving iron deficiency | [Chart note + labs, dated] | | Clinical basis for quantity exceeding standard limit | [Prescriber letter + specific clinical factors] | | Label-consistent dosing rationale | [Reference to FDA label dosing section] | | Prior infusion history (if applicable) | [Dates, quantities, documented clinical response] |

A strong quantity-limit appeal demonstrates both that the FDA label supports the requested quantity and that the individual patient's clinical circumstances justify it. An IRO reviewing this appeal is not bound by Humana's internal quantity-limit policy.